{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:41:53Z","timestamp":1774644113261,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by the expansion of myeloid lineage cells. Chronic myeloid leukemia (CML) is characterized by a BCR-ABL1 fusion gene that causes constitutive tyrosine kinase activity. Polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF) are frequently associated with driver mutations in genes such as JAK2, CALR, and MPL and are mutually exclusive of BCR-ABL1. Herein, we report the first case study of a patient diagnosed with accelerated-phase CML while undergoing treatment for initial JAK2 V617F\u2013positive, BCR-ABL1-negative PMF. This finding emphasizes the importance of BCR-ABL1 testing in patients with an atypical BCR-ABL1-negative MPN disease course.<\/jats:p>","DOI":"10.1093\/labmed\/lmac011","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T12:10:54Z","timestamp":1643371854000},"page":"e140-e144","source":"Crossref","is-referenced-by-count":2,"title":["Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for <i>JAK2<\/i> V617F\u2013Positive Primary Myelofibrosis"],"prefix":"10.1093","volume":"53","author":[{"given":"Jeayeon","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daehyun","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-5044","authenticated-orcid":false,"given":"Miyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Uk","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyun","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongsoo","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eul-Ju","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Jeoung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"1\u20132","key":"2022110311282994600_CIT0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14740\/jh591","article-title":"Emergence of BCR-ABL1 chronic myeloid leukemia in a JAK2-V617F polycythemia vera","volume":"9","author":"Lorenzo","year":"2020","journal-title":"J Hematol."},{"issue":"5","key":"2022110311282994600_CIT0002","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2017.182","article-title":"Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the Bone Marrow Pathology Group","volume":"31","author":"Soderquist","year":"2018","journal-title":"Mod Pathol."},{"issue":"10","key":"2022110311282994600_CIT0003","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1470-2045(07)70295-4","article-title":"Insights into JAK2-V617F mutation in CML","volume":"8","author":"Bocchia","year":"2007","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022110311282994600_CIT0004","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.leukres.2008.03.004","article-title":"Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis","volume":"32","author":"Jallades","year":"2008","journal-title":"Leuk Res."},{"issue":"5","key":"2022110311282994600_CIT0005","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.3816\/CLM.2009.n.080","article-title":"Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation","volume":"9","author":"Pingali","year":"2009","journal-title":"Clin Lymphoma Myeloma."},{"issue":"5","key":"2022110311282994600_CIT0006","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","article-title":"Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia."},{"issue":"7","key":"2022110311282994600_CIT0007","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood-2012-11-467787","article-title":"BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia","volume":"121","author":"Wang","year":"2013","journal-title":"Blood."},{"issue":"7","key":"2022110311282994600_CIT0008","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.leu.2405088","article-title":"JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders","volume":"22","author":"Cambier","year":"2008","journal-title":"Leukemia."},{"issue":"1","key":"2022110311282994600_CIT0009","first-page":"34","article-title":"The concomitant occurrence of JAK2V617F mutation and BCR\/ABL transcript with phenotypic expression\u2014an overlapping myeloproliferative disorder or two distinct diseases? Case report","volume":"6","author":"Ursuleac","year":"2013","journal-title":"J Med Life."},{"key":"2022110311282994600_CIT0010","first-page":"2324709619832322","article-title":"Concurrent JAK2-positive myeloproliferative disorder and chronic myelogenous leukemia: a novel entity? A case report with review of the literature","volume":"7","author":"Bader","year":"2019","journal-title":"J Investig Med High Impact Case Rep."},{"issue":"8","key":"2022110311282994600_CIT0011","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","article-title":"Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis","volume":"21","author":"Bornh\u00e4user","year":"2007","journal-title":"Leukemia."},{"issue":"2","key":"2022110311282994600_CIT0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/6\/e140\/46777056\/lmac011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/6\/e140\/46777056\/lmac011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T11:46:08Z","timestamp":1667475968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/53\/6\/e140\/6542139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,4]]},"published-print":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmac011","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,3,4]]}}}